The proteasome inhibitors bortezomib and PR‐171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells
- 2 March 2007
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 136 (6), 814-828
- https://doi.org/10.1111/j.1365-2141.2007.06504.x
Abstract
Proteasome inhibitors represent a new class of antineoplastic drugs that are considered in the treatment of haematological malignancies. We compared the effects of the reversible proteasome inhibitor bortezomib (Velcade) and the epoxomicin derivative PR-171, an irreversible inhibitor, on primary human acute myeloid leukaemia (AML) cells. Both drugs inhibited autocrine- and cytokine-dependent proliferation of primary AML blasts when tested at nanomolar levels (0.1-100 nmol/l). The antiproliferative effect was independent of basal chymotrypsin-like proteasome activity (showing a 20-fold variation between patients), genetic abnormalities, morphological differentiation and CD34 expression when testing a large group of consecutive patients (n = 54). The effect was retained in cocultures with bone marrow stromal cells. In addition, both drugs enhanced apoptosis. The effect of PR-171 could be detected at lower concentrations than for bortezomib, especially when testing the influence on clonogenic AML cell proliferation. Both drugs had divergent effects on AML cells' constitutive cytokine release. Furthermore, both drugs caused a decrease in proliferation and viability when tested in combination with idarubicin or cytarabine. An antiproliferative effect on primary human acute lymphoblastic leukaemia cells was also detected. We conclude that nanomolar levels of the proteasome inhibitors tested had dose-dependent antiproliferative and proapoptotic effects on primary AML cells in vitro.This publication has 33 references indexed in Scilit:
- Proteasome inhibitors: antitumor effects and beyondLeukemia, 2006
- Therapeutic potential of cytokine and chemokine antagonists in cancer therapyEuropean Journal of Cancer, 2006
- Histone Deacetylase Inhibitor Depsipeptide (FK228) Induces Apoptosis in Leukemic Cells by Facilitating Mitochondrial Translocation of Bax, Which Is Enhanced by the Proteasome Inhibitor BortezomibActa Haematologica, 2006
- Cancer stem cells: AMLs show the wayBiochemical Society Transactions, 2005
- The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycleCell Death & Differentiation, 2005
- Proteasome plasticityFEBS Letters, 2005
- The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implicationsEuropean Journal of Cancer, 2004
- Regulation of apoptosis proteins in cancer cells by ubiquitinOncogene, 2004
- New Strategies in the Treatment of Acute Myelogenous Leukemia (AML): In Vitro Culture of AML Cells—The Present Use in Experimental Studies and the Possible Importance for Future Therapeutic ApproachesThe International Journal of Cell Cloning, 2001
- A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trialBritish Journal of Haematology, 1999